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ABSTRACT 
 
 
  
 This project examines the controversial topic of transgenic animals, and weighs its effects 
on society from both ethical and legal standpoints.  It first focuses on the technology itself by 
describing how transgenic animals are developed, screened, and categorized in chapters-1 and 2. 
Then the transgenic controversy is discussed in Chapters-3 and 4 with ethics and legalities.  
From education, to medicine and industry, transgenic animal research has had an enormous 
impact on society.  Based on the research performed for the project, the authors provide their 
own conclusions about this fascinating technology and whether it should continue. 
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PROJECT OBJECTIVES 
 
 
 The purpose of this project was to investigate transgenic animal research and technology, 
as an example of the effects of technology on society.  This report begins by describing 
transgenic animal methods of creation as well as their purpose, describes the main transgenic 
categories, and then discusses transgenic ethics and laws.  The project aims to help educate the 
reader as to what transgenic animals are, their educational benefits, their applications (from 
medical to the industrial fields), and then finishes with the legal controversies that surround their 
patenting.  This report provides ample information for readers to form their own conclusions as 
to whether they should, or should not, support transgenic animal research. We conclude that with 
sufficient oversight to help ensure the animal’s welfare, transgenic research should continue.  
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CHAPTER-1:  TRANSGENIC ANIMAL TECHNOLOGY 
Richard Breault 
 
 
Transgenic animals are a subset of genetically modified organisms that contain a foreign 
gene inserted in the genome that gives the animal a new property. Transgenic animals have 
become a major part of biomedical research, providing new disease models for screening 
therapies, new ways for manufacturing medicines, providing organs for transplant, or providing 
new food sources.  The purpose of this chapter is to describe transgenic technology and how 
these animals are created which will serve as a background for later chapters discussing their 
ethics and legal issues. 
 
What is a Transgenic Animal? 
Transgenic animals typically are described as those containing a foreign gene(s) inserted 
into their DNA for the purpose of giving the animals new properties.  These types of transgenic 
animals are referred to as “knock-ins” because a new gene has been inserted in the genome, and 
this usually increases expression of a particular gene.  However, more loosely, transgenic 
animals sometimes include other categories of animals in which a particular gene has been 
removed (knock-out animals) or in which the expression of a particular gene is decreased 
(knock-down animals).   
Chapter-2 will discuss the various categories of transgenic animals in detail, but 
transpharmers are one example.  These animals have been engineered to produce human 
pharmaceuticals (hormones, antibodies, enzymes) in their milk or blood.  In this case, the 
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animals serve as a type of living bioreactor to perform a complex biochemical synthesis.  
Generally the protein being produced is harvested from a secreting system (liver, kidney, or 
mammary glands) in a large mammal (e.g. goats, sheep, or cow).  Milk is the preferred 
production fluid because the animal is not sacrificed or bled to obtain the product (Betsch, 1995).  
Human proteins often need complex chemical additions (such as glycosylation) to be fully 
active, and tissues like mammary glands are capable of performing these reactions.  Mammals 
are constantly manufacturing their own proteins, so the foreign gene is expressed using the 
animal’s own synthetic machinery.   
A second type of transgenic animal example is Superfish (Figure-1).  This is a type of 
genetically modified food source whose growth hormone gene has been placed under the control 
of a promoter that is always switched on (Devlin et al., 1997).  This engineering allows the fish 
to continually produce growth hormone year round, unlike normal fish that produce it seasonally, 
so the fish grows to large size quickly and on less food.  These kinds of examples will be 
discussed in detail in Chapter-2. 
 
 
 
 
 
 
 
Figure-1:  A Transgenic Animal Example, Superfish.  The smaller 
fish in the front is a normal salmon, about 13 inches long weighing 2.8 
pounds, while the Super Salmon in the back born at the same time grew 
to about 24 inches and 6.6 pounds (Anakupto, 2011)   
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How Are Transgenic Animals Created? 
Transgenic animals are created using genetic engineering technology developed over the 
past several decades.  Recombinant DNA (rDNA) technology allows scientists to excise specific 
DNA fragments or genes, amplify them, and insert them into other genomes.  rDNA technology 
can be used to fuse different species’ DNA together, allowing new DNAs to be created that did 
not exist in nature.  The process is inefficient, and the offspring must be screened to identify 
which animals, if any, took up the transgene.   
Generally, there are two main methods for creating transgenic animals, pronuclear 
manipulation, and manipulation of embryonic stem (ES) cells.  These methods are both designed 
to get the same end result, but are done in very different ways, each with advantages and 
disadvantages.  Pronuclear manipulation is much simpler, faster, and produces an animal with all 
cells containing the transgene, but the process is very inefficient, and the DNA is incorporated 
randomly.  ES cell manipulation allows a pre-screening process to ensure the transgene is 
incorporated into the ES cells prior to implantation, and also allows targeting of specific areas of 
the genome, but it often produces a mosaic animal that must be bred to obtain full transgenics 
(Ceci, 2011). 
 
Pronuclear Manipulation 
Pronuclear manipulation was the first method used to insert foreign DNA into a host.  In 
this process, the first step is to decide which DNA to insert.  The inserted DNA usually has three 
parts:  the transgene itself which encodes the desired new trait, the promoter which dictates 
which tissue will express the transgene, and the cloning vector which allows the DNA to be 
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amplified and purified.  The cloning vector is usually plasmid or viral DNA.  The vector allows 
safe passage of the DNA into the host.   
Next, an egg is fertilized in vitro, and incubated.  Before the male and female pronuclei 
fuse to make the zygote, a micropipette is used to inject the transgene DNA into one of the 
pronuclei (Figure-2).  Because of its larger size, usually the male pronucleus is injected.   The 
DNA is incorporated randomly into the genome, if at all, which can sometimes be unfavorable to 
the embryo.  If the transgene does insert into the genome, all derived cells of the offspring will 
be transgenic.  The injected egg is then incubated until about day-5 when a blastocyst forms, then 
is implanted into the uterus of a foster mother for development.   
 
 
 
 
 
 
 
 
 
Figure-2:  Microinjection of Foreign DNA Into a Pronucleus.  This 
figure shows one of the two main ways for creating transgenic animals.  
Shown are a suction pipette (diagram left side) which holds the newly 
fertilized egg (diagram center) in place for microinjection, and the 
injection pipette (right side of the diagram).  (DNA Microinjection, 
2011) 
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After birth, the offspring are tested for the presence of the transgene.  Only a small 
percent of the offspring will have taken up the transgene, and only a subset of those will be 
expressing it.  Often, the offspring are mated with each other to select for another generation of 
transgenics with a higher level of expression (Kimball, 2011). Just like any other scientific 
experiment, there are drawbacks to this pronuclear microinjection method.  Depending on where 
the transgene inserts in the genome, the position can affect the animal’s survival.  The site of 
integration can also affect the level of transgene expression; if the gene inserts randomly into an 
active area of the chromosome it can be strongly expressed, but if it randomly inserts into an 
inactive area of the chromosome it can be silenced.  Many companies are trying to find new 
ways to minimize these problems
 
(Krejci and Boccaccio, 2006). 
 
Embryonic Stem Cell Manipulation 
The second method for creating a transgenic animal is to manipulate embryonic stem 
(ES) cells.  ES cells are the inner cell mass of the 5-day old blastocyst (Figure-3), and are 
relatively undifferentiated pluripotent cells that will eventually form all types of cells in the adult 
body.   Advances in stem cell research have allowed ES cells to be isolated from blastocysts, and 
grown in culture to make ES cell lines (Martin, 1981).  The ES cells can be treated with 
engineered viruses carrying transgenes to allow DNA integration, then can be selected in culture.  
The selection process often includes growing on a selection medium containing an antibiotic like 
neomycin; the transgene DNA can include a gene encoding antibiotic resistance, so only the cells 
containing the transgene will grow.  Once the ES cell line has been shown to have incorporated 
the transgene, the ES cells are injected into a blastocyst, and the blastocyst is implanted into a 
foster mother as before (Boghossian et al, 2008).  However, not all the cells of the blastocyst are 
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transgenic (only the injected cells were), so offspring created by this procedure are mosaics, with 
some cells being transgenic and others not.  So after offspring are born, they are usually inbred to 
select for pure transgenics (Transgenic Animal Science, 2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-3: Diagram of Embryonic Stem Cells.  This figure denotes the 
second main method for creating transgenic animals.  Newly fertilized 
eggs (diagram upper left) are grown to the blastocyst stage (upper right), 
from which embryonic stems cells are isolated from the inner cell mass 
(diagram center).  The ES cells can be grown into an ES cell line, which 
is then treated with engineered viruses carrying transgenes.  The cells are 
screened to select for transgenics, then implanted into a new blastocyst.   
(Boghossian et al., 2008) 
 
In addition to allowing engineered cells to be screened for the presence of the transgene 
prior to injection, the other main advantage of this technique over pronuclear microinjection is it 
allows the use of homologous recombination.  In this process, the transgene DNA contains large 
portions of host chromosome that recombine with their respective areas of the host DNA 
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replacing it (Bronson and Smithies, 1994).  This allows the foreign transgene to be inserted into a 
specific site in the host DNA to avoid activating any deleterious genes, or to avoid insertion in an 
inactive area of the host DNA. 
 
Screening for Transgenic Positives 
As mentioned above, the production of transgenic animals is not an efficient process, so 
offspring must be screened to identify positive transgenics.  Screening can be done a variety of 
ways; Southern blots or PCR can be used to identify animals that incorporated the transgene into 
their genome, while Northern blots or RT-PCR can be used to identify animals expressing the 
transgene.  Southern blots (Figure-4) are used to identify a transgenic DNA fragment from 
within a mixture of genomic fragments (Southern, 1975).  The animal’s DNA is isolated, then 
cut with restriction enzymes to fragment it.  The DNA fragments are then separated by size using 
electrophoresis, and the pattern of fragments is blotted to a membrane.  The membrane is then 
hybridized to a radioactive probe complementary to the transgene.  If the animal contains the 
transgene, its fragment will be present on the membrane, and it will hybridize to the probe 
allowing a visual signal.  In order to see whether the radioactive probe hybridized to any 
fragment on the membrane, the membrane is exposed to x-ray film.  The presence of radioactive 
signal is seen as black bands on the film (McGraw Hill, 2011). 
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Figure-4:  Diagram of a Southern Blot Used to Screen Transgenic 
Positives.  In this process, DNA is cut by restriction enzymes, then 
separated by size using electrophoresis (upper right).  The pattern of 
DNA fragments is blotted to membrane (upper left), and then hybridized 
with a probe for the transgene to allow it to base pair with a 
complementary transgene DNA fragment if present.  (Southern Blot 
Methods, 2001) 
 
 
The second main method for detecting the presence of the transgene is polymerase chain 
reaction (PCR) (Figure-5).  PCR is used mainly to amplify specific regions of DNA located 
between two primers.  If PCR primers are used that flank a particular transgene sequence, that set 
of primers will amplify the transgene if it is present in the animal’s genome.  A PCR reaction 
contains the target DNA (in this case the animal’s DNA), the two types of primers (in this case 
for the transgene hopefully inserted in the transgenic animal), Taq polymerase (a heat stable 
enzyme used to replicate DNA), and DNA nucleotides (used as precursors to incorporate into the 
growing DNA chains. The temperature of the PCR reaction is controlled by a programmable 
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thermocycler.  The reaction is slowly heated to about 93°C to separate the double-stranded 
template DNA. After strand separation, the reaction is cooled to around 60°C to allow the DNA 
primers to bind their complementary regions.  After the primers bind, the reaction is warmed to 
about 72°C, the optimum temperature of Taq polymerase, to allow DNA synthesis from the 
primer sites.  This creates two newly synthesized strands of target (transgene) DNA (PCR, 
2007).  The cycle of strand denaturation, primer annealing, and DNA synthesis is repeated about 
30 times to amplify the region of DNA located between the primer sites.  The so called amplicon 
(amplified DNA) is then visualized by electrophoresis, or can be seen in real time using 
fluorescent nucleotides.  This technique not only allows us to determine whether an organism 
contains the transgene, it also allows amplification of that DNA for further manipulation if 
needed.  Because the target gene is copied so many times, it is easy to visualize. 
 
 
 
 
 
Figure-5:  Diagram of PCR.  This process is 
used to amplify a region of target DNA (in 
this case the transgene) to determine whether 
it is present in the transgenic animal.  The 
process involves repeating a programmed 
cycle of DNA denaturation, primer annealing, 
and DNA elongation.  (PCR Process, 2010) 
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Breeding Transgenics 
 Transgenic offspring are often bred with each other to create transgenic lines that 
increase expression of the transgene, or (in the case of chimeric animals) that contain a higher 
percent of cells containing the transgene.  Transgenic animals tend to breed normally.  
Sometimes, chimeric animals are bred with wild type animals to produce heterozygous offspring.  
If these are then bred to each other, there is a 25% chance that two chimeric animals will produce 
a fully transgenic animal. After a few generations, animals are created in which all cells contain 
the transgene. 
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CHAPTER-2: TRANSGENIC APPLICATIONS 
Tania Emmanuelle Torchon 
 
 Transgenic animals are genetically engineered animals that express new, desired 
properties of a foreign gene inserted into their genome.  Because of transgenic technology, the 
scientific and medical benefits to society appear endless.  These animals can be altered to 
produce life-saving pharmaceuticals in their milk; they can be engineered to produce organs for 
transplant; or they can be used as disease models to help understand disease progression and 
cures.  Their genetic codes can be adjusted to enhance their size, or they can be altered solely to 
study the function of a newly discovered gene.  This chapter will discuss various transgenic 
categories, and provide examples of societal benefits within each category as a prelude to the 
next chapter on transgenic ethics. 
 
Disease Models 
Aside from studying infected human patients, one alternative to studying diseases is to 
use live animal models.  In fact, human clinical trials often cannot proceed unless new drugs or 
treatments are first tested on animals.  But some human diseases are not carried by animals, so to 
study these types of diseases new animal models must be created.  Transgenics takes care of this 
problem by allowing human genes to be inserted in an animal’s genome. 
 
Alzheimer’s Mouse 
 Alzheimer’s disease (AD) is the most common type of neurodegenerative disease, and its 
patients are expected to drastically increase in the new few decades with our ageing population.   
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The complete cause of AD is unknown, however scientists have some understanding of 
genetically inherited early-onset cases.   The brains of AD patients become riddled with senile 
plaques (composed of amyloid-beta protein) (Aβ) and neurofibrillary tangles (composed of 
abnormal tau protein).  While these toxic plaques and resulting tangles occur at low frequencies 
as a result of old age in those not afflicted with AD, researchers have found that AD patients 
develop both abnormal structures very rapidly and primarily in areas responsible for memory 
(Alzheimer’s Association 2004).  
Aβ is a neurotoxin that kills neurons.  This protein is formed from amyloid precursor 
protein (APP) on the surface of neurons and glial cells.  Early-onset AD patients often have APP 
mutations that lead to the formation of more Aβ neurotoxin (Goate et al., 1991).  Animals do not 
normally get AD (except for some great apes which are not a convenient model to work with), so 
to mimic AD in animals, scientists inserted human genes with mutated APP into mice. 
The world’s first true working model for AD was created in 1995 by Professor David S. 
Adams of Worcester Polytechnic Institute and his fellow researchers from the former Transgenic 
Sciences Incorporated (TSI), who successfully created mice expressing mutant forms of human 
APP (Games et al., 1995).  After about 6 to 9 months, these AD-mice develop toxic Aβ and 
senile plaques, and show considerable brain damage in the hippocampus; however 
neurofibrillary tau protein buildup within the neurons was not observed (Games et al., 1995). 
This significant observation eventually led to the finding that although Aβ initiates AD, and by 
itself initiates brain damage, the production of abnormal tau is a required downstream event for 
making a more comprehensive model of the disease (Access Excellence, n.d.). 
The creation of this AD-mouse line, opened many doors for screening drugs to block Aβ 
formation, and was directly used by Elan Pharmaceuticals (South San Francisco) to create the 
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world’s first AD vaccine.  The vaccine cleared Aβ from the brain (Schenk et al., 1999).  The 
vaccine proved successful in decreasing the concentration of the plaques in older subjects, while 
mice treated at a young age showed no signs of Aβ or senile plaque formation.  Subsequently, 
the FDA granted a fast track designation to the most effective of Elan’s vaccines, and in 
December 2007 human trials began (Elan Corporation, 2009). 
 
Oncomouse 
   The OncoMouse is another very successful transgenic animal. With funding from 
Dupont, this mouse line was created by Harvard and National Institute of Health (NIH) 
researchers Timothy Stewart and Philip Leder in the 1980s (Stewart et al., 1984).  As the name 
would suggest, OncoMouse is a genetically engineered laboratory mouse designed to have an 
increased susceptibility to developing cancer, which can be used for studying cancer formation 
or for screening anti-cancer drugs. The original OncoMouse, also known as the Harvard Mouse, 
contained somatic cells and germ cells with a myc oncogene under the control of a mouse 
mammary tumor virus (MMTV) promoter.  This promoter is switched on in mammary tissues, so 
oncomice develop mammary tumors, usually adenocarcinomas (Stewart et. al., 1984; Bioethics 
and Patient Law, 2006).   The creators of the original OncoMouse eventually patented their 
method of engineering cancerous transgenic mice and the OncoMouse trademark name, with 
DuPont as the owner of the rights to the invention (Leder and Stewart, 1984; DuPont 
Technology, 2008).  So these mice became the world’s first patented animals, which will be 
discussed in Chapter-4. 
Since the creation of the first cancer-susceptible mouse, many other methods of inducing 
cancer in mice have arisen. For example, if mice are generated as either homozygous or 
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heterozygous for knocking out tumor suppressor p53, as the mice mature, because their p53 is 
not present to help correct for DNA mutations that can lead to tumor formation, the mice are 
highly susceptible to developing malignant lymphoma and osteosarcomas, respectively (Harvey 
et al., 1993).  As another example, if mice are made heterozygous for a nonsense mutation in 
their Apc genes, they become increasingly more susceptible to intestinal adenomas (Jacoby et al., 
1996).  Yet another type of transgenic Oncomouse contains the v-Ha-ras oncogene driven by the 
MMTV promoter.  These mice become increasingly susceptible to benign hyperplasia and 
develop tumors in mammary, lymphoid, and salivary tissues (Sinn, 1987).  
 
Transpharmers 
Transpharmer animals are another major success of transgenics.  These animals allow 
scientists to produce life-saving drugs in the milk of farm animals.  This is done by engineering 
the gene encoding the protein drug to be under the control of a milk protein promoter, like casein 
or lactoglobulin, so the drug is expressed in the milk.  The protein can then be purified directly 
from the milk without sacrificing the animal (Biotechnology Information Series, 1995; Gillespie, 
2010).  This process is not harmful to the animal, and gathering the protein is simple, the animal 
need only be milked (Walsh, 2007). 
Before transpharming, human therapeutic proteins were either isolated from large 
quantities of donated cadaver organs, or were produced by microbial bioreactors using 
recombinant DNA technology.  Microbial production does not work for complex proteins that 
require post-translational reactions such as glycosylation to yield a biologically active drug 
(Janne et al., 1992). Although the use of the microbial bioreactors was relatively inexpensive, the 
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process sometimes produced inactive drugs.  Mammary tissue is capable of the full range of 
post-translational processing steps. 
 
Transpharmer Goats 
 A very notable transgenic goat was announced to have been created in May of 1999 by 
Genzyme Transgenics Corporation (Framingham, MA), Louisiana State University, and Tufts 
University School of Veterinary Medicine (Grafton, MA).  Human Antithrombin III (ATIII) is a 
protein found in human plasma that helps prevent blood clotting. In October and November of 
1998 at Genzyme Transgenics’ farm in Massachusetts, three healthy identical cloned female 
goats were born containing the human ATIII gene under control of a milk protein promoter, of 
which one produced ATIII in its milk (Genzyme Transgenics, 1999).  
In 1999, the transpharmed ATIII protein was in phase-III clinical trials to be evaluated as 
an effective anticoagulant for patients following cardiopulmonary bypass surgery.  In February 
of 2009, the FDA approved ATIII for those with hereditary antithrombin deficiencies (HD) 
undergoing high risk surgeries to prevent the patients from having peri-operative hemorrhaging, 
during operation, and post operation thromboembolic events.  In Europe, transpharmed ATIII 
was approved for surgical use in HD patients by the European Commission as early as 2006 
(ATryn, 2008).   
 
Transpharmer Sheep 
 Human factor–IX protein is very important in blood coagulation, and if it is deficient (as 
in hereditary bleeding disorders such as hemophilia-B) it renders blood unable to clot.  The only 
treatment for this disorder is to administer factor IX protein to patients.  However, before 
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transpharming, the only method for obtaining the necessary factor was the extraction from 
human plasma, which can contain HIV or hepatitis C virus, and blood screening increased costs 
(Schnieke et al., 1997). 
In 1989, scientists designed a hybrid gene encoding human factor-IX under the control of 
a milk protein promoter, and inserted it into sheep. Two ewes were designed to carry 10 foreign 
copies of the gene.  Researchers found that each ewe successfully secreted factor-IX in their 
milk, deeming the experiment a success (Clark et al., 1989).  
 
Xenotransplanters 
Xenotransplantation is the implantation of cells of one species into another species. 
Xenotransplanters are donor animals that are genetically manufactured to prepare their organs for 
transplantation into human recipients. The front runners considered for these xenotransplants are 
pigs, as scientists say that pig organs are better than those of chimpanzees or baboons because 
their size is better suited for the human body, pig physiology is similar to humans, and pigs are 
already routinely slaughtered for food (Fabregas, 2006). Although this field of transgenics is 
relatively new, the use of pigs to help save human lives is far from new; pig heart valves have 
transplanted to diseased patients for years (Catez, 2005).  Presently, in the United States, ten 
patients die each day waiting for organ transplants (U.S. Food and Drug Administration, 2009). 
The need for organs far outweighs the availability, which may be why scientists have begun 
looking to xenotransplantation as a viable option.  
Pigs produce sugars called alpha-1,3-galactose on the surface of their cells that human 
immune systems recognize as foreign, causing immuno-rejection (Pearson, 2001).  Scientists 
have successfully identified two gene alleles that are responsible for the production of these 
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sugars, and have managed to knock out one of them.  But they still have to knock out the other 
allele.  When the University of Pittsburgh Medical Center (UPMC) and Revivicor Inc. came 
together on a farm in Blacksburg, Virginia, they engineered 200 pigs to lack alpha-1,3-
galactosyltransferase, the enzyme that adds galactose onto the cell surface which is viewed as 
foreign by humans.  In 2002 and in 2003, some of these organs were transplanted into baboons 
(Pearson, 2003). The baboons received the genetically altered pig organs and survived nearly six 
months.  The problem was formation of tiny blood clots that worsened over time. Now these 
scientists are putting human anticoagulant genes into the pigs as a method of solving the 
problem.  
One potential problem associated with intermingling species is the possibility of 
spreading diseases. Some viruses, such as swine flu, can jump between species causing 
pandemics.  So scientists argue pigs used for this purpose should be screened for known viruses.   
The US FDA required Revivicor to screen all pigs for a myriad of bacteria and viruses 
(Fabregas, 2006). 
 
Transgenic Food Sources 
To better accommodate food for an ever expanding population, some animals have been 
genetically modified to allow them to grow larger and faster.  These experiments failed with 
mammals, but have shown some success with fish (Harper, 2006). 
 
Super Fish 
In aquaculture, trout and salmon have been genetically modified to grow larger than their 
normal non-transgenic counterparts.  To test whether science could increase the rate of growth to 
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help production rates, Rainbow trout eggs were microinjected with DNA construct 
“OnMTGH1”, containing a salmon gene that over-expresses growth hormone under the control 
of a metallothionein promoter that is always switched on. This allows the trout to produce 
growth hormone year round instead of seasonally.  The results were successful, as the injected 
trout matured much faster than the wild type; however in this particular experiment the trout did 
not surpass the wild type in size (Devlin et al., 2001).  Unfortunately, the animals died before 
reaching sexual maturation, and were observed to have both cranial abnormalities and reduced 
viability (Devlin et al., 2001).  
In a second experiment, Pacific salmon were engineered to contain a Chinook salmon 
growth hormone gene driven by a Pout antifreeze protein promoter.  These salmon grew 11 times 
faster than their wild type counter parts and were larger (Harper, 2006).  Four out of five of these 
fish reached sexual maturity, and were able to pass the transgene onto offspring (Devlin et al., 
1995).  Unlike the Rainbow trout experiment, the Salmon showed increased growth rates, 
improved flesh color, and increased disease resistance, while eating less food.  They even 
survived even after their tank had been frozen (Devlin et al., 1997).  These fish, marketed by 
Aquabounty Technologies (Waltham, MA), are close to obtaining FDA approval for human 
consumption, and if so would become the world’s first approved transgenic animals for 
consumption (Aquabounty Technologies, 2011). 
 
Super Pig 
The goal of the Superpig experiment was to create a pig that grew larger and faster, but 
ate less food.  A DNA cassette containing an ovine growth hormone gene under the control of a 
metallothionein promoter (always on) was microinjected into 400 zygotes, and 15 transgenic 
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pigs were born.  The liver, kidney, adrenal, thyroid, carcass fat and subcutaneous fat of all 
transgenic littermates were larger and thicker than their non-transgenic littermates (Pursel et al., 
1997).  Another type of Superpig was genetically modified in 1989 in Beltsville Maryland, 
containing the human growth hormone gene instead of the ovine version (Miller et al., 1989).   
Unfortunately, the Superpigs suffered from a number of terrible side effects, including kidney 
and liver problems, uncoordinated walk, thickened skin, ulcers, joint disease, heart disease, 
bulging eyes, and pneumonia, so the animals were euthanized (Rollin, 1996).  This series of 
mammalian growth hormone experiments failed, which resulted in a voluntary suspension by 
scientists of all transgenic growth hormone experiments on farm animals.  
  
Transgenic Scientific Models 
This category of transgenic animals includes animals constructed to provide information 
on the function of specific proteins in vivo.  Some of these animals are engineered to over-
express certain proteins, while others have the genes encoding the protein knocked out to 
eliminate its expression. Some successful examples in this category include Doogie the Smart 
Mouse, ANDi the Monkey, and AlphaMUPA mice that eat less and live longer. All of these 
transgenic animals have opened many doors for further study.  
For example, Doogie the Smart Mouse was engineered to over-express the gene encoding 
NR2B, a subunit of the NMDA receptor that predominates when the brain is young, and can 
presumably help the animals learn faster (Tang et al., 1999).  The gene also controls the brain’s 
ability to associate different related events, one of the foundations of learning (Harmon, 1999).  
ANDi was the world’s first transgenic primate, and he was engineered to contain a 
jellyfish gene encoding green fluorescent protein (GFP) (Chan et al., 2001).  Although he was 
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transgenic, containing the GFP gene, he did not express it so his cells did not glow fluorescent 
green.  But he proved transgenic technology can be applied to primates, so this technology might 
be expanded to primates in the future (Vogel, 2001).  
AlphaMUPA mice were engineered to express urokinase-type plasminogen activator in 
the brain.  These mice eat 20% less and live 20% longer than wild type mice, however their legs 
had tremors.  The animals had much more plasma corticosterone (a stress hormone) when young, 
but a significantly reduced amount when old.  These little fountains of youth offer scientists a 
method of studying delayed aging at the systemic and single-cell levels (Miskin et al., 1999). 
 
Transgenic Applications Conclusion 
 The transgenic animals discussed above were created with different goals in mind for 
benefitting society.  Because of these animals, more is known about Alzheimer’s disease and  
cancer, while some serve as bioreactors producing life-saving medicines.  Some transgenic 
animals may make it possible to help prevent human starvation, while others teach us about how 
the brain learns new information.  This chapter served to introduce the reader to the various types 
of transgenic animals, and serves as a prelude to facilitate the project’s later discussions of 
transgenic ethics and laws.  
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CHAPTER-3: TRANSGENIC ETHICS 
Tania Emmanuelle Torchon 
 
 
 A chimera is a mythical creature composed of  parts of various animals. Human 
imagination has enabled chimeras to live on for centuries without truly inhabiting the earth. 
Some of the most famous range from the monstrous fire-breathing Greek Chimera that was 
composed of the body of a lion, head of a goat, and tail of a snake, to the Hindu and Buddhist 
Garuda that was half man and half eagle (Kimbrell, 1994).  From a genetic point of view, a 
chimera is an organism containing altered DNA from two or more genetically distinct organisms; 
nowadays, these creatures are known as transgenic animals. Although chimeras were once 
thought of as fantasies, transgenic sciences have opened the doors for unimaginable fiction to 
become fact.  However unlike the mythical chimeras, the purpose of creating transgenic animals 
is for society’s benefit. The purpose of this chapter is to discuss the topic of whether transgenic 
animals should be created. 
 
Framing the Transgenic Ethical Question 
Transgenic ethics is a balancing act between the benefits to society versus the potential 
harm to the animals. Some of these transgenic animal designs are brilliant because modern 
science has invented ways to allow genes to be mixed between species. However brilliant they 
may be, society still holds many qualms about this research as some of the animals endure much 
pain. From the DuPont OncoMouse that can suffer with advanced tumor formation, to 
transpharmers and ANDi the monkey that do not suffer at all, transgenic ethics has proven to be 
impossible to cover with one blanket policy.  And some animals provide strong medical benefits, 
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while others were constructed simply to see whether that species could be made transgenic.  
Consequently, strength of the benefits to society versus the suffering of the animals can be a 
gauge as to whether certain transgenic experiments should continue. This chapter will discuss the 
ethical status of specific transgenic examples, while providing author conclusions on which 
experiments should continue.  
 
Disease Models Ethics  
 A disease model is an animal genetically altered to carry and express a disease gene 
normally found in humans, as previously discussed in Chapter-2. These animals are necessary to 
disease research to help screen treatments and test cures before implementing such treatments in 
humans.  The question stands as to whether inflicting these animals with deadly diseases (or 
portions of the disease process) is worth the benefit to society (Christiansen and Sadoe, 2000). 
Chapter-2 discussed two very successful but very different transgenic animals: the Alzheimer’s 
mouse and the OncoMouse. 
 
Alzheimer’s Mouse Ethics 
 The first example of a disease model to discuss is the Alzheimer’s mouse. Alzheimer’s 
disease (AD) cannot be prevented, cured, or slowed, and it ultimately leads to death.  It is the 
sixth leading cause of death in the United States, and there are an estimated 5.4 million people 
currently suffering with it (Alzheimer’s Association, 2011).  The sum of the direct (patient care) 
and indirect costs (caregiver loss of work hours) of Alzheimer’s disease and its related dementias 
is $183 billion dollars as estimated for 2011 (Alzheimer’s Association, 2011).  In the US, every 
70 seconds someone develops Alzheimer’s disease (Elan Corporation, 2009). 
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As previously mentioned, the AD mouse was created in 1995 (Games et al., 1995) and 
mimics the early stages of AD as seen in humans.  The mouse line develops neurotoxic Aβ 
plaques and shows damage in its hippocampus, an area of the brain related to memory.  So the 
mouse is useful for screening drugs and developing vaccines to block the early stages of AD.  
However, the mice do not get the complete disease; unlike humans, the mice show no mutated 
tau protein buildup that normally form neurofibrillary tangles (Games et al., 1995). The South 
San Francisco branch of Elan Pharmaceuticals used this mouse model to develop the world’s 
first vaccine for AD that showed great promise in the mice (Schenk et al., 1999), and is now in 
human clinical trials.  
With respect to the mice, there has been no report of any measurable pain or suffering 
endured by the AD mice. The mice play normally, eat normally, and reproduce normally.  Their 
reduced memory would surely play a factor if they were competing for survival in the wild, but 
they live in laboratories with few to no survival skills required.  The mice do not appear to suffer 
by any measurable criteria, they have increased our understanding of AD initiation, and they 
served as a required step for developing potential AD treatments.   
The proof of their value lies with the billions of research dollars currently being spent by 
various pharmaceutical companies on inhibitors and vaccines whose purpose is to decrease the 
formation of toxic Aβ and remove existing senile plaques from neural tissue, based on data 
obtained from AD mice (Elan Corporation, 2009).  Substantial medical advancements have been 
made possible with AD mice, with the animals’ welfare intact, so where’s the harm in continuing 
experiments on this disease model?  
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Oncomouse Ethics 
In 2010, an estimated 1.5 million people worldwide, and a half a million Americans, were 
diagnosed with cancer (American Cancer Society, 2010). On the complicated end of disease 
model ethics lays the Harvard and Dupont OncoMouse. This model was originally created in 
1982 (Stewart et al., 1984) containing a c-myc oncogene under the control of a mammary tumor 
virus promoter.  The promoter drives the expression of the oncogene in mammary tissue, so the 
mice are prone to mammary adencocarcinomas.  This mouse model can be used to screen new 
treatments for cancer, just as the AD mouse does for AD.  The model has taught scientists a great 
deal about cancer and why tumors form.  However, unlike AD mice, Oncomice can indeed 
suffer, depending on the stage of tumor formation prior to sacrifice. 
Yes, animals are unable to clearly communicate their levels of pain and suffering, but 
why would their tolerance levels not be analogous to those of human patients suffering from 
cancer’s afflictions?  This is a valid reason for stopping experiments if possible prior to advanced 
tumor formation by euthanizing the mice. However, the 1.5 million people suffering from 
cancer, and their families and friends, are strong benefiters of the information learned from this 
mouse line.  Institutional Animal Care and Use Committees (IACUCs) should use strong 
oversight to mandate euthanasia before unnecessary pain and suffering develops. These mice 
have provided scientists with an excellent opportunity to learn about tumor formation and to 
develop treatments, so the experiments should continue with strong oversight. 
 
Transpharmers Ethics 
 A transpharmer is an animal engineered to express a foreign gene (usually a gene 
encoding a desired human drug) in their mammary glands.  The drug is produced and secreted 
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into the milk without needing to sacrifice the animal. Transpharmer species produced to date 
include mice, goats, sheep, and cows.  Using these animals allows for easy purification of the 
drug, low manufacturing costs, and the wellbeing of the animal is kept intact. 
Before transpharming, therapeutic proteins were often obtained through cadaver organs 
(always in short supply) or produced cheaply but inefficiently with microbial bioreactors. But 
microbes are unable to produce active complex protein drugs because they lack some of the 
necessary post-translational processing capabilities (Janne et al., 1992).  Mammary tissue is able 
to complete these complex post-translational processing steps and has allowed several drugs to 
be manufactured.  
For example, transpharmer goats were created in 1999 that can produce human anti-
thrombin blood thinning protein ATIII in their milk.  ATIII is currently used in Europe on 
antithrombin-deficient patients undergoing surgery to minimize clotting (ATryn, 2008).  This 
drug was also the first FDA-approved transpharmed product in the US.  There have been no 
reports of transpharmers suffering (for those that survive the transgenic process), yet they 
produce lifesaving medicines, therefore these experiments should continue. 
 
Xenotransplantation Ethics 
In the United States, currently there are 111,812 people awaiting an organ donation.  
Eighteen people die each day waiting for an organ, while one organ donor can save 8 lives (U.S. 
Department of Health and Human Services, 2011). These numbers become of even greater 
concern when considering that in 2010 there were only 14,502 organ donors in the United States 
(Donate Life, 2011). Although 8 lives are saved with one organ donor, some of the donors aren’t 
compatible with the patients, so the desired organ is rejected.   
 34 
Xenotransplanters are transgenic animals engineered to produce organs histo-compatible 
with humans.  Their ability to mass produce organs could give hope to those awaiting 
transplants.  Surprisingly, pig physiology is very similar to that of humans, so pigs are preferred 
for xenotransplantation (Fabregas, 2006).  Caution must be used however, as pigs can carry 
viruses that infect humans.  But this could be minimized by screening the pigs for known viruses.  
Considering the chaos caused by the H1N1 influenza virus that once affected swine, cross 
species infection should be intensely supervised. 
Should pigs be raised for organ donation?  The author of this chapter says yes.  Pig heart 
valves have been transplanted into humans for years, and pigs are already routinely slaughtered 
for food, so harvesting their organs in addition to using their meat is not that different.  Swine 
organs are usually thrown away after slaughter, other parts are fed to pets, and other meat is used 
for human consumption. Why not use all of the pig rather than just a portion?  If a pig is to be 
slaughtered for consumption, why not collect it’s organs for transplantation also? 
 
Transgenic Food Sources Ethics 
In 2009 there were 50.2 million Americans living in food insecure homes with 17.2 
million of these Americans being children (Feeding America, 2011). Supply and demand is the 
economic system that governs the world; as demand increases without supply increasing, prices 
increase, and the poor are left to fend for themselves. Transgenic food sources are genetically 
enhanced plants and animals that mature at a more rapid rate and are larger in size compared to 
their wild type counterparts. When discussing transgenic animal food source ethics, Superpig and 
Superfish, as previously mentioned in Chapter 2, are great examples of both unsuccessful and 
successful transgenic food source animals, respectively. 
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Superpig Ethics 
 The goal of superpig was to create a pig that provided more meat, in less time for the 
increasing food demand.  Superpig was created in 1989 in Beltsville, Maryland, and contained a 
human growth hormone gene under the control of a strong always-on promoter (Miller et al., 
1989).  However, the first super pig was a disaster and the animal suffered serious health 
problems, including kidney and liver problems, uncoordinated walk, thickened skin, ulcers, joint 
disease, heart disease, bulging eyes, and pneumonia, so the animals were euthanized (Rollin, 
1996).  Due to this experience, scientists proposed a voluntary moratorium on performing growth 
hormone experiments in mammals. 
Aside from Superpig’s suffering, the animal may not have been a good food source 
anyway. Unhealthy animals that can barely stand should not be released to the public. These 
animals spread diseases and are routinely euthanized for human’s sake, and to protect their herds.  
The author is against performing mammalian growth hormone experiments. Yes hunger 
worldwide is increasing, but consuming unhealthy food is not the answer.  
 
Superfish Ethics 
 The goal of Superfish was similar to that of Superpig, grow a fish larger in less time on 
less food.  As mentioned in Chapter-2, the Super Pacific Salmon grew 11 times faster than their 
wildtype counter parts and were less susceptible to diseases. These fish were so superior to their 
wildtype, they were able to survive even after being frozen (Devlin et al., 1997). And unlike 
Superpig, these aquacultures of Superfish seem to have exhibited no pain or side effects. Because 
of the superb progress made with SuperFish experiments, the FDA is close to approving the 
world’s first transgenic animal manufactured for human consumption (Aquabounty 
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Technologies, 2011).  In addition, Aquabunty’s Superfish were engineered to be sterile, so they 
cannot mate with wildtype fish if they escape their aquafarming cages.  The author is in favor of 
Superfish experiments continuing, so long as no health effects to the fish are noticed. 
 
Transgenic Scientific Models Ethics 
 The transgenic scientific models discussed in Chapter-2 are engineered to over-express or 
eliminate expression of specific proteins. The examples discussed were Doogie the Smart Mouse 
(that overexpressed the NR2B subunit of the glutamate receptor), ANDi the not so fluorescent 
monkey (who was supposed to express green fluorescent protein), and the long living 
AlphaMUPA mice (who over-expressed urokinase). These three animal examples were all 
normal with no reports of pain, yet they increased our knowledge of the function of specific 
proteins.  The ability of scientific models to expand our knowledge is incredible.  Some of the 
animals were even superior to wild type counterparts.  The author of this chapter is generally in 
favor of this category of transgenic animal, based on the knowledge gained. 
 
Chapter-3 Conclusions 
This chapter discussed the ethical concerns of the five different categories of transgenic 
research: Disease Models, Transpharming, Xenotransplantation, Food Sources, and Scientific 
Models.  It discusses how some cases of transgenic animal research should continue to open 
doors to some of the vital problems that plague society, while others should not be pursued at the 
expense of another living creature’s wellbeing.  It also discusses how one policy should not 
govern all experiments, as the benefits to society and effects to the animals vary considerably. 
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Although some animals appear to suffer a great deal (SuperPig and OncoMouse), some don’t 
suffer at all (Alzheimer’s mouse, transpharmers, Doogie the Smartmouse), therefore a blanket 
policy on all transgenic animals is both unrealistic and unfair to the potential breakthroughs that 
this technology has to offer.   
With respect to disease models, the author of this chapter believes the experiments with 
Alzheimer’s mouse should continue (there is no pain to the animal, yet the medical benefits have 
been strong), and experiments with Oncomouse should be strongly overseen by IACUC 
committees to minimize animal suffering by either using painkillers or by early euthanasia.  The 
author is also generally in favor or transpharmers (no animal suffering while saving lives with 
their medicines), Xenotransplanters (pigs are already being slaughtered for food so why not get 
their organs too), Scientific Models (we have too much to gain by creating them), and Food 
Source sources like Superfish (but not Superpig).  
As previously mentioned, transgenic ethics is a balancing act between the benefits to 
society versus the potential harm to the animals. As demonstrated in this chapter, the balance 
should be weighed on the case by case basis, and not with one blanket utilitarian policy.  
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CHAPTER-4:  TRANSGENIC LEGALITIES 
Richard Breault 
 
Because the use of transgenic animals is controversial, laws have been enacted to regulate 
transgenesis and the production of these animals (Ladas, 2003).  In addition to these rules, some 
animals have been patented, which raises the question of whether such patents should be 
allowed.  This chapter will discuss the patenting of transgenic animals. 
 
US Patent Requirements 
According to the US Patent and Trade Office (US PTO, 2005) to patent something the 
inventor must demonstrate three basic requirements:  novelty (the invention must be something 
new, not previously invented), non-obviousness (so an expert in the same particular field of 
study would not easily come up with the same idea), and utility (there must be a purpose to the 
new invention).  The law states “a claimed invention is deemed useful if… it is capable of 
providing some identifiable benefit.  The benefit must be specific, substantial, and practical.” 
(US PTO, 2005). 
In addition to these requirements comes a set of applications and paperwork. If approved, 
the inventor has rights to the patent for 20 years (US PTO, 2005), so other people do not have the 
right to manufacture, sell, import, or use the same invention without direct compensation (Garza, 
2007).  The PTO states that an inventor “who invents or discovers any new and useful process, 
machine, manufacture, or composition of matter… may obtain a patent therefore, subject to the 
conditions and requirements of the [US PTO]” (BitLaw, 2000). 
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The First Patented Organism 
 Prior to patenting animals, a legal precedence was required for patenting any life form.  
This precedence was the case of Diamond v Chakrabarty, 1980.  In this case, microbiologist 
Chakrabarty engineered a Pseudomonas bacterium containing two plasmids carrying genes for 
metabolic enzymes that allowed the microbe to digest oil.  The microbe was to be used to digest 
oil slicks (Figure-1).  The patent was initially filed in 1972, but it was challenged because the 
patent examiner concluded the patent could not be granted because microbes are natural, living 
organisms, not “compositions of matter”. There was no precedent for patenting life.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-1: Advertising Poster for Chakrabarty’s Oil-Eating Microbe.  
This picture was posted in China to inform people what bacterium was 
cleaning up their BP oil spill (Palomi, 2010) 
 
In the appeal, Chakrabarty argued that the engineered bacterium was novel and did not 
naturally exist in nature, so it should be classified as a “composition of matter”.  This specific 
ability is not possessed by any other organism known to man and therefore is a creation by man. 
Using this logic, Chakrabarty appealed to the PTO Board of Appeal and eventually won the 
acceptance of his patent in 1980, so the world was given its first patented organism, described as 
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a “live, human-made micro-organism” (Diamond vs. Chakrabarty, 1980). This landmark case 
opened the door for the further patenting of transgenic animals. 
 
United States Oncomouse Case 
In 1984, four years after the acceptance of Chakrabarty’s patent, Philip Leder and Dupont 
attempted to patent a transgenic animal known as Oncomouse (Figure-2). Oncomouse was 
originally created for cancer and tumor research (Stewart et al., 1984), and contained a myc 
oncogene under the control of a hormonally inducible mouse mammary tumor virus promoter.  
The promoter caused expression of the oncogene beyond its normal levels in mammary tissue, 
causing mammary adenocarcinomas.  The mouse is used to study cancer formation by 
oncogenes, and to screen anti-cancer drugs (WIPO, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure-2: The Harvard Oncomouse. 
(Harvard, 2007) 
 
For four years, the issues of whether animals should be patented, and the benefits to 
society versus animal suffering were argued.  While the Oncomouse case was under 
consideration, in 1987, another case involving polyploidy oysters was considered which affected 
the outcome of the Oncomouse case.  The case considered whether the polyploidy oysters were 
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patentable subject matter.  The case ended by the US PTO announcing that “non-naturally 
occurring, non-human, multicellular living organisms, including animals, are patentable subject-
matter within the scope of the Statute” (Schutt, 2004), which opened the floodgates for animal 
patents including the Oncomouse (although the animal cases caused more arguing with animal 
rights activists, farmers, etc). 
After much debate, in 1988 the US PTO granted patent #4,736,866 to produce non-
human transgenic animals with oncogenes inserted into their DNA (filed as Leder and Stewart, 
1984).  Leder went on to claim additional patents on preparing cell cultures from non-human 
transgenics (Leder and Stewart, 1992), and on the testing method for mice expressing an 
oncogene (Leder and Stewart, 1999). 
 
European Oncomouse Case 
 The European Patent Office (EPO) had a different stance on the patenting of Oncomouse. 
In this case, initially the EPO concluded the patent did not fully meet requirements of a patent 
therefore most claims were accepted except the mouse itself.  The EPO initially stated that 
patents do not cover animals and that this patent was immoral (WIPO, 2006).  But eventually the 
EPO decided to apply a utilitarian test to weigh the potential of the mice to benefit society via 
helping develop medical treatments for cancer patients versus the potential pain suffered by the 
mice.  The EPO eventually concluded that the medical possibilities grossly outweighed the 
potential negative outcomes to the mice (WIPO, 2007), so finally in 1992, the EPO approved the 
patent for Oncomouse (Sharples and Curley, 2009).  However, the patent was restricted only to 
mice. 
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Canadian Oncomouse Case 
 Besides filing patents in the US and Europe, Harvard also applied for Oncomouse patents 
in Canada and Japan (Check, 2002).  Canada decided to go in the opposite direction as Europe 
and the US.  They saw Oncomouse itself as uninventive. The claims to the techniques and means 
of making Oncomouse were accepted, but the mouse itself was not, as engineered animals was 
not included in the definition of an invention (WIPO, 2006). 
 
Japanese Oncomouse Case 
 Japan followed in the footsteps of the US and Europe in being generally favorable to 
patenting animals. The Japanese Oncomouse patent was accepted much faster than the US and 
European patents, because Japan did not have a provision excluding biological inventions (unless 
they violated a morality clause).  In Japan, as well as Europe, the animal itself, and the 
production of said animals is patented (Schutt, 2004). 
 
Current FDA Laws on Transgenesis 
 The US FDA oversees “articles (other than food) intended to affect the structure or any 
function of the body of man or other animals” (FDA, 2009), so the FDA watches over every part 
of transgenesis, from the initial construction of the recombinant DNA, to how the animals are 
maintained and transported.  According to the FDA the only difference between a “normal” 
animal and a genetically engineered (GE) animal is the presence of rDNA which provides a new 
trait to the animal.  Animals that obtained their rDNA in the embryonic stage, can breed and pass 
on their GE DNA because it resides in all cells including their gametes.  Based on feedback from 
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scientists and opponents, the FDA created new streamlined regulations for these animals and 
their products (FDA, 2009).  In order to patent an animal or transpharmed drug, they must pass 
through seven categories:  
1. Definition- what are claims made, and what is the novel drug. 
2. Construct- how was the rDNA made. 
3. Lineage- how has a strain of the described transgenic performed over generations. 
4. Phenotype- provide evidence that the animals are in good health. 
5. Durability- prove there will be no change in production of drug over time. 
6. Safety- provide evidence to the safety of the environment and, if used for food, to the 
consumer. 
7. Validation- provide evidence the final product does what you say it does. 
 
Even though some scientists view the FDA as sometimes detrimental to science because 
they can slow the process of patenting, with the creation of the new streamlined guidelines for 
filing transgenic patents, the hope is to increase both ease of the process and the safety to animals 
and the consumers.   
 
Should Life Be Patented: Pros and Cons 
 Many good things have come for society from the patenting of organisms.   And even 
though transgenics can aid medical research they are still changing the natural genetic code of 
these animals. The patenting of these animals allows the creator of to maintain legal rights to 
his/her creation for 20 years to attempt to sell it to make money.  For the patented period, any 
scientist wishing to use the invention/creation must get approval from, or compensate the 
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inventor.  In general, this is a good thing because it protects the inventor from losing credit for 
his/her invention, and allows money to flow into the company to stimulate further research.  
However, in some cases, the licensing fees were so high that some scientists feared only 
the wealthy labs could afford to work with the animals, leaving out the smaller labs.  This was 
the case with Oncomouse when Harvard and Dupont first applied their licensing fees.  DuPont 
wanted to charge for the use of Oncomouse in drug screening and company-related experiments 
but allowed free research licenses for “noncommercial studies”.  So all entities had to register 
and comply with basic licensing terms, but the license was free for non-profits.  Some groups 
argued that these fees could slow down testing and that they marred science as a whole.  Some 
even argued that the patent would not hold up if challenged in court, but no such claims have 
been filed to date.  Although the price of a license is a major factor, the mere fact that the patent 
covers such a broad spectrum of transgenic animals is more of a problem. Either way, DuPont 
still has rights to Oncomouse and any cancer-induced transgenic mouse (Marshall, 2002). 
Also on the negative side of allowing transgenic patents are the concerns of 
environmentalists who are worried that transgenic animals may escape into the wild to breed 
with their wild type counterparts spreading the transgene.  In the case of Aquabounty’s 
Superfish, who grows to a large size in aqua-farming (Aquabounty Technologies, 2011), 
environmentalists were worried the large salmon would escape and outbreed normal salmon.  
However, Aquabounty engineered the fish to be sterile, so in this case the argument is 
minimized. 
Also on the negative side are animal rights activists who argue scientists should pay 
closer attention to animal suffering.  Animal rights activists say that the pain an animal must 
endure must not be overlooked, even with extreme advancements in medicine to help minimize 
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the suffering (Letterman, 2007).  While some activists believe that animal pain should be 
minimized and weighed against the positives coming out of the research, other activists see only 
the negative side and want to stop all further animal testing.  The welfare of the animals should 
be important to both “man-made” and naturally occurring animals.  Some activists argue that 
simply giving these mice cancer is in direct violation of their rights, but the scientific governing 
groups of animal protection state that animal rights and animal welfare are not the same, and that 
they cannot support animal rights activists whose beliefs condemn the responsible use of animals 
for the betterment of human society (Arnold, 2001).   
Since the original patenting of Oncomouse, the US PTO has approved hundreds of 
animal patents.  Without a doubt, transgenic animals have benefited society, and likely will 
continue to do so in the future, however I agree that animal suffering should be minimized.  
Institutional IACUC committees should provide strong oversight to ensure the least number of 
animals are used in testing, that animals are quickly euthanized if necessary, and that painkillers 
are used appropriately.  
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PROJECT CONCLUSIONS 
 
 
 
 From purpose, to creation, to the many moral and legal issues surrounding transgenic 
animals to date, this IQP report covers it all.  Transgenic animals are genetically engineered 
animals that contain, and may express, foreign genes that have been inserted into their genome. 
They can be created by a number of methods and have various applications. However, as 
beneficial as research on these animals may be to scientific growth and to society’s health, a 
number of ethical and legal concerns surround these creatures. 
 Transgenic animals are typically created by either microinjecting the transgene into the 
pronucleus of a fertilized egg, or by manipulating embryonic stem (ES) cells.  The former 
usually creates animals in which all the cells of the body are transgenic, while the latter 
technique produces chimeras that need to be bred to make pure transgenics. 
Transgenic applications have five primary classes: Disease Models, Transpharmers, 
Xenotransplanters, Food Sources, and Scientific Models, all discussed in chapter two.  The 
disease model class of transgenic animals enables researchers to study the progression of human 
diseases on animals to help find cures.  Transpharmers produce lifesaving medicines in their 
milk that are otherwise produced inadequately by other technologies.  One transpharmed drug 
ATryn has already been FDA approved to help prevent thromboembolisms in antithrombin 
deficient patients. Organs are a precious asset, spare organs are even more precious and very 
scarce.  Xenotransplanter research gives hope to patients facing death with an exclusively 
engineered pig organ alternative that is less likely to be rejected by the host immune system.  
Fish designed to grow larger, faster, while consuming less food may make it possible to reduce 
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the human hunger statistic.  Transgenic biological models offer scientific knowledge of specific 
protein function in vivo unattainable by other means. 
 Chapter three explores ethical issues related to transgenic animals.  It leads with a 
statement outlining the debate as a balancing act between animal welfare and the medical, 
educational, and industrial advantages to society.  The chapter poses important questions that 
encourages the reader to form their own opinions of whether the line between animal discomfort 
and society’s benefit has been crossed in specific cases.   Chapter four discussed some of the 
legal issues associated with transgenic animals, including the advantages and disadvantages of 
patenting animals. 
As for the opinion of the authors, based on the research performed in this project, we 
believe that most experiments on transpharming, xenotransplantation, scientific modeling, AD 
disease modeling, and fish aquaculture food enhancement should continue, as these reportedly 
posed little to no harm to the animals, while providing strong benefits to society.  However, the 
authors believe that other types of transgenic experiments, including Oncomouse experiments 
with advanced tumor formation (that involves pain to the animal) and mammalian growth 
hormone experiments (like Superpig) should cease until better methods are found, as these 
animals have been reported to suffer much pain.  For Oncomice experiments, administering 
euthanasia prior to severe disease progression should be considered as an alternative, or even 
administering pain killers throughout the entire research process. However, because there is no 
direct way for the animals to report their levels of pain, and the integrity of the diseases’ 
progression may be affected by outside medications, the best method is to completely suspend 
these types of experiments for now.  With respect to Superpig experiments, the authors believe 
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that when the animals can barely move because of severe joint pain, all forms of research with 
the animals should cease and the affected animals should immediately be euthanized. 
Overall, based on the findings of this project, the authors believe in general that all five 
major classes of transgenic animals should be continued, but with caution for those types of 
experiments that have no strong medical benefits to society or that involve animal suffering.  
And in all cases, every effort should be made to minimize any animal suffering if it occurs.  The 
authors also believe that transgenic fish should be approved by the FDA to help fight world 
hunger, but agree that any “Super mammals” (such as Superpig) should be disallowed.  In all 
cases, strong legislative oversights should be followed to help ensure that any experiments gone 
wrong lead to immediate animal euthanasia. 
 
